PharmaCyte Biotech, Inc.
PMCB
$1.64
-$0.12-6.82%
| 10/31/2024 | 07/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -14.01% | 9.41% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.83% | 8.81% | |||
| Operating Income | 12.83% | -8.81% | |||
| Income Before Tax | -106.27% | 1,639.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -106.27% | 1,639.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -106.27% | 1,639.17% | |||
| EBIT | 12.83% | -8.81% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -114.80% | 960.36% | |||
| Normalized Basic EPS | 121.28% | -58.72% | |||
| EPS Diluted | -117.87% | 817.29% | |||
| Normalized Diluted EPS | 121.28% | -58.72% | |||
| Average Basic Shares Outstanding | -2.92% | -5.80% | |||
| Average Diluted Shares Outstanding | -2.92% | -5.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
